Fig. 7From: Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysisSubgroup meta-analysis of progression-free survival (PFS) and overall survival (OS). (2.1) Nivolumab alone or in combination with Ipilimumab versus chemotherapy in PFS; (2.2) Nivolumab alone or in combination with Ipilimumab versus chemotherapy in OS. CI: 95% confidence intervalBack to article page